Cardiovascular disease risk assessment and multidisciplinary care in prostate cancer treatment with ADT: recommendations from the APMA PCCV expert network
Review of books or of software
Full Text
View Full-text in CUHK Digital Object Identifier (DOI) DOI for CUHK Users  |
Altmetrics Information
.
Other information
AbstractPurpose: Androgen deprivation therapy (ADT) is the mainstay approach for prostate cancer (PCa) management. However, the most commonly used ADT modality, gonadotropin-releasing hormone (GnRH) agonists, has been associated with an increased risk of cardiovascular disease (CVD). Methods: The PCa Cardiovascular (PCCV) Expert Network, consisting of multinational urologists, cardiologists and oncologists with expertise in managing PCa, convened to discuss challenges to routine cardiovascular risk assessment in PCa management, as well as how to mitigate such risks in the current treatment landscape. Results: The experts identified several barriers, including lack of awareness, time constraints, challenges in implementing risk assessment tools and difficulties in establishing multidisciplinary teams that include cardiologists. The experts subsequently provided practical recommendations to improve cardio-oncology care for patients with PCa receiving ADT, such as simplifying cardiovascular risk assessment, individualising treatment based on CVD risk categories, establishing multidisciplinary teams and referral networks and fostering active patient engagement. A streamlined cardiovascular risk-stratification tool and a referral/management guide were developed for seamless integration into urologists’ practices and presented herein. The PCCV Expert Network agreed that currently available evidence indicates that GnRH antagonists are associated with a lower risk of CVD than that of GnRH agonists and that GnRH antagonists are preferred for patients with PCa and a high CVD risk. Conclusion: In summary, this article provides insights and guidance to improve management for patients with PCa undergoing ADT.
Acceptance Date05/02/2024
All Author(s) ListMerseburger AS, Bakshi G, Chen DY, Chiong E, Jabbour M, Joung JY, Lai AY, Lawrentschuk N, Le TA, Ng CF, Ng CT, Ong TA, Pang JS, Rabah DM, Ragavan N, Sase K, Suzuki H, Teo MMH, Uemura H, Woo HH
Journal nameWorld Journal of Urology
Title of PublicationWorld Journal of Urology
Year2024
Month3
Day14
Volume Number42
Issue Number1
PublisherSpringer Link
ISSN0724-4983
eISSN1433-8726
LanguagesEnglish-United Kingdom
KeywordsCardiovascular disease, Prostate cancer, Interdisciplinary, Risk management, Androgen deprivation therapy, Cardiovascular toxicity
